351 related articles for article (PubMed ID: 11067958)
1. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.
Stockmeyer B; Elsässer D; Dechant M; Repp R; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
J Immunol Methods; 2001 Feb; 248(1-2):103-11. PubMed ID: 11223072
[TBL] [Abstract][Full Text] [Related]
3. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
[TBL] [Abstract][Full Text] [Related]
4. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.
Otten MA; Rudolph E; Dechant M; Tuk CW; Reijmers RM; Beelen RH; van de Winkel JG; van Egmond M
J Immunol; 2005 May; 174(9):5472-80. PubMed ID: 15843545
[TBL] [Abstract][Full Text] [Related]
5. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
6. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
[TBL] [Abstract][Full Text] [Related]
7. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
Pascal V; Laffleur B; Debin A; Cuvillier A; van Egmond M; Drocourt D; Imbertie L; Pangault C; Tarte K; Tiraby G; Cogné M
Haematologica; 2012 Nov; 97(11):1686-94. PubMed ID: 22689689
[TBL] [Abstract][Full Text] [Related]
8. Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.
van Spriel AB; van den Herik-Oudijk IE; van Sorge NM; Vilé HA; van Strijp JA; van de Winkel JG
J Infect Dis; 1999 Mar; 179(3):661-9. PubMed ID: 9952373
[TBL] [Abstract][Full Text] [Related]
9. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
Stadick H; Stockmeyer B; Kühn R; Schrott KM; Kalden JR; Glennie MJ; van de Winkel JG; Gramatzki M; Valerius T; Elsässer D
J Urol; 2002 Feb; 167(2 Pt 1):707-12. PubMed ID: 11792958
[TBL] [Abstract][Full Text] [Related]
12. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
Stockmeyer B; Schiller M; Repp R; Lorenz HM; Kalden JR; Gramatzki M; Valerius T
Br J Haematol; 2002 Sep; 118(4):959-67. PubMed ID: 12199773
[TBL] [Abstract][Full Text] [Related]
13. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
[TBL] [Abstract][Full Text] [Related]
14. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
[TBL] [Abstract][Full Text] [Related]
16. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
[TBL] [Abstract][Full Text] [Related]
17. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
18. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
Glorius P; Baerenwaldt A; Kellner C; Staudinger M; Dechant M; Stauch M; Beurskens FJ; Parren PW; Winkel JG; Valerius T; Humpe A; Repp R; Gramatzki M; Nimmerjahn F; Peipp M
Leukemia; 2013 Jan; 27(1):190-201. PubMed ID: 22660187
[TBL] [Abstract][Full Text] [Related]
19. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
[TBL] [Abstract][Full Text] [Related]
20. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
Heijnen IA; Glennie MJ; van de Winkel JG
Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
